Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy

This study has been completed.

Sponsor:

Collaborators:

National Cancer Institute (NCI)

National Institutes of Health (NIH)

Rockefeller University

Information provided by:

Memorial Sloan-Kettering Cancer Center

ClinicalTrials.gov Identifier:

NCT00700167

First received: June 17, 2008

Last updated: April 19, 2011

Last verified: April 2011

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	April 2011
Primary Completion Date:	April 2011 (Final data collection date for primary outcome measure)

No publications provided by Memorial Sloan-Kettering Cancer Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Romano E, Rossi M, Ratzinger G, de Cos MA, Chung DJ, Panageas KS, Wolchock JD, Houghton AN, Chapman PB, Heller G, Yuan J, Young JW. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res. 2011 Apr 1;17(7):1984-97. Epub 2011 Feb 25.

To Top